Will the increased prevalence of nonalcoholic steatohepatitis (NASH) in the age of better hepatitis C virus therapy make NASH the deadlier disease?

Authors

  • Mary E. Rinella M.D.

    Corresponding author
    1. Department of Medicine Northwestern University Feinberg School of Medicine Chicago, IL
    • Department of Medicine, Northwestern University Feinberg School of Medicine, 303 East Chicago Avenue, Searle 10-563, Chicago, IL 60611
    Search for more papers by this author
    • fax: 312-908-6192


  • See Article on Page 1208

  • Potential conflict of interest: Nothing to report.

No abstract is available for this article.

Ancillary